Upadacitinib,
does it really help with Induction and maintenance of clinical remission in moderate-to-severe ulcerative colitis?
research showsThe grade is C. In the 473-patient U-ACHIEVE efficacy analysis, week-8 remission was 26% versus 5%, adjusted difference 21.6 points (95% CI 15.8 to 27.4). In the 515-patient U-ACCOMPLISH analysis it was 34% versus 4%, difference 29.0 points (23.2 to 34.7). The 52-week maintenance trial also succeeded, but all three trials belonged to one AbbVie development program, giving C with 54 points.
ads claimThe week-8 induction and week-52 maintenance differences are real, but they should not be described as confirmation by independent programs. Existing verdict 833 is B with 70 points for rheumatoid arthritis, a different indication.
Useful facts when choosing a product
- All three trials were multicenter, double-blind, placebo-controlled studies using adapted Mayo clinical remission as the primary endpoint.
- The Lancet article identifies AbbVie as funder and lists several AbbVie employees as coauthors.
- Randomized and efficacy-analysis totals differed: 474 versus 473 and 522 versus 515 in the induction trials.
Chamgap Semantic Classification Code
Candidate index · review held
M.upadacitinib.oral.induction-and-maintenance-of-clinical-remission-in-moderate-to-severe-ulcerative-colitis.maintain.placeboMedicinal interventions > Upadacitinib > Oral > Induction and maintenance of clinical remission in moderate-to-severe ulcerative colitis > Maintenance claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
U-ACHIEVE randomized 474 participants, 319 versus 155, but analyzed 319 versus 154 who received at least one dose. Remission was 83/319 (26%) versus 7/154 (5%), adjusted difference 21.6 points (95% CI 15.8 to 27.4), P<0.0001. U-ACCOMPLISH randomized 522, 345 versus 177, and analyzed 341 versus 174: 114/341 (34%) versus 7/174 (4%), difference 29.0 points (23.2 to 34.7), P<0.0001. Maintenance rerandomized 451 induction responders and found remission in 63/148 (42%), 80/154 (52%), and 18/149 (12%) with 15 mg, 30 mg, and placebo, respectively, all P<0.0001.
Why this is classified as C (54)
Large direct remission benefits appeared in replicate induction and 52-week maintenance trials, but all decisive evidence came from one manufacturer program, giving C with 54 points.
Counterpoint. C does not mean no effect; it caps certainty because independent confirmation is missing.
Rejudgment record. Cross-check applied — Large absolute differences on induction and maintenance primary endpoints, limited by a single AbbVie development program
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Induction of clinical remission at week 8 | C | Absolute differences were 21.6 and 29.0 points, but both trials came from one manufacturer program. |
| Maintenance of clinical remission at week 52 | C | Both doses outperformed placebo, but the evidence remains within the same development program. |
| Symptomatic remission including stool frequency and rectal bleeding | C | Adapted Mayo remission repeatedly improved, but no independent program has confirmed it. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Danese et al. 2022 U-ACHIEVE and U-ACCOMPLISH induction trials | Phase 3 multicenter double-blind placebo-controlled randomized trials | 474 randomized and 473 analyzed for efficacy; 522 randomized and 515 analyzed | AbbVie | Adapted Mayo clinical remission at week 8 | 26% versus 5%, difference 21.6 points (95% CI 15.8 to 27.4); 34% versus 4%, difference 29.0 points (23.2 to 34.7); both P<0.0001. | Replicate induction trials within one manufacturer program |
| Danese et al. 2022 U-ACHIEVE maintenance trial | Rerandomized double-blind placebo-controlled maintenance trial among induction responders | 451 in the primary analysis, 148/154/149 | AbbVie | Adapted Mayo clinical remission at week 52 | 42% with 15 mg, 52% with 30 mg, and 12% with placebo; adjusted differences 30.7 and 39.0 points, both P<0.0001. | Supports maintenance efficacy within the same manufacturer program |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Upadacitinib x clinical remission in ulcerative colitis — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/upadacitinib-ulcerative-colitis-clinical-remission/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.